James Foster, MD
Vascular Surgery · Iowa City, IANPI 1760617922
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 75.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $15,402 and has fallen 93.3% since, to $1,035 in 2025. Among vascular surgery clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $133.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- W. L. Gore & Associates, Inc.$3K
- Endologix LLC$2K
- Silk Road Medical, Inc.$2K
- Penumbra, Inc.$434
- Boston Scientific$308
- plus $1K from 23 others
Across 1 payment — averaging $325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$325
What the payments were for
- Consulting fees$7002%
- Speaking & faculty fees$16,08846%
- Travel & lodging$8,14823%
- Food & beverage$9,82428%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 97 | $26,254 |
| W. L. Gore & Associates, Inc. | 45 | $2,934 |
| Endologix LLC | 7 | $1,950 |
| Silk Road Medical, Inc. | 36 | $1,616 |
| Penumbra, Inc. | 16 | $434 |
| Boston Scientific | 13 | $308 |
| Bard Peripheral Vascular, Inc. | 5 | $286 |
| Solventum Corporation | 1 | $173 |
| Johnson & Johnson(2 entities) | 6 | $138 |
| Urgo Medical North America, LLC | 3 | $137 |
| Abiomed | 4 | $118 |
| Mimedx Group, Inc. | 6 | $104 |
| Smith+Nephew | 3 | $53 |
| Mozarc Medical US LLC | 2 | $39 |
| Davol Inc. | 1 | $29 |
| Aroa Biosurgery Incorporated | 1 | $28 |
| Surgenex LLC | 1 | $27 |
| Medline Industries LP | 2 | $22 |
| BD | 1 | $20 |
| Biocompatibles, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Bolton Medical Inc | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Merck | 1 | $14 |
| Lemaitre Vascular, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDURANT IIS$12,278
- IN.PACT Admiral$6,716
- HawkOne$4,388
- Ovation$1,236
- GORE TAG Thoracic Endoprosthesis$1,156
- ENROUTE Transcarotid Neuroprotection System$981
- ENHANCE Transcarotid Peripheral Access Kit$981
- ENROUTE Transcarotid Stent System$819
- ENROUTE 0.014 Guidewire$819
- AFX$700
- Heli-FX EndoAnchor System$595
- GORE EXCLUDER Iliac Branch Endoprosthesis$254
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$190
- PREVENA$173
- V.A.C. VERAFLO$173
- VIABAHN VBX Balloon Expandable Endoprosthesis$172
- ENROUTE Transcarotid Stent$162
- ENROUTE .014 Guidewire$162
- GORE VIABAHN Endoprosthesis with Heparin$141
- GORE VIABAHN VBX Balloon Expandable Endo$130
How this compares
$34,833 in reported general payments places this provider in the 90th percentile of 38 vascular surgery providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $11,249 |
| XareltoRivaroxaban | 12 | $9,669 |
| ClopidogrelClopidogrel Bisulfate | 113 | $1,238 |
| Gabapentin | 11 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $138 | $9,66912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 vascular surgery providers in Iowa.
Other vascular surgery in Iowa City
- Luigi PascarellaIowa City$16K
- Natalie WegerIowa City$14K
- Jun XuIowa City$11K
- Megan ParrottIowa City$6K
- Jeanette ManIowa City$6K
- Dongjin SuhIowa City$6K
- Adeola OdugbesiIowa City$5K
- Victor HatcherIowa City$3K
- Crystal RodriguezIowa City$2K
- Nanette ReedIowa City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.